Profile

Business Description

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

Company Info

Address:
#1203-4464 Markham Street
Victoria, BC V8Z 7X8
Canada

Telephone:
(250) 744-2487

Fax:
(250) 708-4345

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical and Medicine Industry (3741)